Drug Type Small molecule drug |
Synonyms Mosapride Citrate, Mosapride citrate dihydrate, Mosapride citrate hydrate (JP17) + [10] |
Target |
Action agonists |
Mechanism 5-HT4 receptor agonists(Serotonin 4 (5-HT4) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (30 Jun 1998), |
Regulation- |
Molecular FormulaC27H37ClFN3O12 |
InChIKeyKVKIQHMTGSGTFO-UHFFFAOYSA-N |
CAS Registry636582-62-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01994 | Mosapride Citrate Hydrate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Gastritis | China | 31 Aug 2005 | |
Urinary Calculi | China | 01 Jan 1999 | |
Chronic gastritis | Japan | 30 Jun 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dyspepsia | Phase 3 | South Korea | 12 Dec 2016 | |
Gastrointestinal dysfunction | Phase 2 | China | 18 Oct 2024 |
Not Applicable | - | izurhakfcf(spvcbpsrpc) = pcnsueriow lfxymxifyc (ngadxvkaig ) View more | Positive | 15 Oct 2023 | |||
Placebo | izurhakfcf(spvcbpsrpc) = cmevagstiv lfxymxifyc (ngadxvkaig ) View more | ||||||
Not Applicable | Dyspepsia hydrogen | methane | - | igmocisuqg(cxyndgldjt) = ncdwoovwrc srpdtdovid (yzpecjqslk ) | Negative | 22 May 2022 | ||
igmocisuqg(cxyndgldjt) = tkvvlsytbk srpdtdovid (yzpecjqslk ) |